


Investment Objective and Benchmark Index

The Biotech Growth Trust PLC (the "Company") seeks capital appreciation through investment in the worldwide biotechnology industry. Performance is measured against its benchmark index, the NASDAQ Biotechnology Index (sterling adjusted).

Five Year Performance (%)

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed; an investor may receive back less than the original amount invested.



— Share Price (total return) +20.5%
 — Net Asset Value per share (total return) +19.4%
 — Benchmark: NASDAQ Biotechnology Index (sterling adjusted) +29.8%

Source: Morningstar, Index - Bloomberg.

Ten Largest Holdings as at 30 September 2022 (% of total investments)

Name	Total
Argenx	4.7
Sarepta Therapeutics	4.7
Ionis Pharmaceuticals	4.7
BioMarin Pharmaceutical	4.6
Syndax Pharmaceuticals	4.5
Yisheng	4.3
Aclaris Therapeutics	4.2
Mersana Therapeutics	3.8
Neurocrine Biosciences	3.8
Biogen	3.6
Total	42.9



Portfolio Manager Geoffrey Hsu



OrbiMed
 Healthcare Fund Management

Fast Facts As at 30 September 2022

Launch Date	June 1997
AIC Sector	Biotechnology & Healthcare
Date of Appointment of OrbiMed	19 May 2005
Annual Management Fee (payable by the Company)	0.65% of net assets plus 0.30% per annum on the Company's market capitalisation up to £500m, 0.20% on market capitalisation above £500m to £1bn and 0.10% on market capitalisation over £1bn
Performance fee	See Annual Report for details
Ongoing Charges Ratio (OCR) *	1.1%
Continuation Vote	2025 AGM and every 5th AGM thereafter
Year / interim end	31 March / 30 September
Capital Structure	40,082,396 Ordinary Shares of 25p

Trust Characteristics

Number of Holdings	64
Net Assets (£m)	£424.8m
Market Capitalisation (£m)	£398.4m
Dividend Policy	It is not anticipated that the Company will pay a dividend
Gearing (AIC basis)	6.5%
Leverage**	Gross 106.5% Commitment 106.5%
Share Price (p)	994.00
NAV (p)	1059.71
(Discount) / Premium	(6.2%)
Portfolio Turnover p.a.	97.4%
Active Share***	75.1%

The Biotech Growth Trust PLC

Information as at 30 September 2022

Geographical Breakdown as at 30 September 2022 (%)

North America	77.0%
Continental Europe	10.1%
*Unquoted	9.4%
China (quoted)	2.2%
United Kingdom	1.3%

Total **100.0%**

* No more than 10% of gross assets will be invested in unquoted investments at the time of acquisition. This limit includes any investment or commitment to invest in private equity funds managed by OrbiMed or an affiliate thereof. Investments or commitments to invest in such private equity funds will be limited to US\$15m, after the deduction of proceeds of disposal and other returns of capital. Of the 9.4% unquoted investments, 8.9% was in China and 0.5% was in Asia.

Source: All portfolio information sourced from Frostrow Capital LLP

Discrete Performance – Calendar Years (%)

Percentage Growth 12 Month Return	2017	2018	2019	2020	2021	YTD
NAV	9.9	-14.3	47.4	52.4	-23.1	-10.3
Share Price	12.1	-19.9	48.5	67.7	-24.6	-16.3
Index	10.5	-3.8	19.6	22.1	0.2	-3.1

Standardised Discrete Performance (%)

Percentage Growth 12 Month Return	Sep 17-Sep 18	Sep 18-Sep 19	Sep 19-Sep 20	Sep 20-Sep 21	Sep 21-Sep 22
NAV	0.9	-17.1	86.5	-4.2	-20.1
Share Price	0.4	-15.7	94.3	-11.1	-17.6
Index	12.8	-13.5	29.6	14.6	-10.4

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed.

Source: NAV (total return; fully diluted) & Share Price (total return) – Morningstar. Index - Bloomberg.

*Calculated at the financial year end, includes management fees and all other operating expenses, excludes performance fees.

**The Board has set the leverage limit for both the Gross and the Commitment basis at 130% of the Company's Net Asset Value.

***Active Share is expressed as a percentage and shows the extent to which a fund's holdings and their weightings differ from those of the fund's benchmark index. A fund that closely tracks its index might have a low Active Share of less than 20% and be considered passive, while a fund with an Active Share of 60% or higher is generally considered to be actively managed.


Codes

Sedol	0038551
ISIN	GB0000385517
Legal Entity Identifier (LEI)	549300Z41EP32MI2DN29
Global Intermediary Identification Number (GIIN)	U1MQ70.99999.SL.826
Bloomberg	BIOG LN
EPIC	BIOG

Investment Policy

In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. The Company will not invest more than 15% of the value of its gross assets in any one individual stock at the time of acquisition. No more than 10% of gross assets will be invested in unquoted investments at the time of acquisition. This limit includes any investment or commitment to invest in private equity funds managed by OrbiMed or an affiliate thereof. Investments or commitments to invest in such private equity funds will be limited to US\$15m, after the deduction of proceeds of disposal and other returns of capital. The Company's borrowing policy is that borrowings will not exceed 20% of the Company's net assets. The Company may be unable to invest directly in certain countries. In these circumstances, the Company may gain exposure to companies in such countries by investing indirectly through swaps. Where the Company invests in swaps, exposure to underlying assets will not exceed 5% of the gross assets of the Company at the time of entering into the contract.

Return vs Volatility (5 Years Annualised) – Chart (%)



Commentary

In September, the NAV per share was down 0.4%, the share price was up 2.6% and the benchmark NASDAQ Biotechnology Index (sterling adjusted) was up 1.9%.

The biotech sector outperformed the broader markets in September, with continued weakening of the British pound versus the U.S. dollar helping to offset negative U.S. dollar returns for the month. Macro themes such as fears over inflation, rising interest rates, and the possibility of a recession-inducing hard economic landing continue to dominate price action of the broader markets. After posting a strong August, small and midcap biotech gave back some of those gains in September. The Company's heavy overweighting in small-cap biotech led to underperformance versus the benchmark index, but we continue to believe the small-cap segment has the most opportunity for upside from current levels. Overall, our bullish outlook remains unchanged, with the sector still trading above the June lows and companies with positive catalysts rewarded with share price appreciation and healthy investor demand for financings. We continue to be selective and invest in companies with relatively de-risked assets and healthy balance sheets that can sustain them through potential value-creating clinical catalysts.

On the M&A front, one notable deal announced in September was Novo Nordisk's acquisition of Forma Therapeutics for \$1.1 billion, representing an approximately 50% premium to Forma's pre-announcement share price. The deal came shortly after Pfizer's announcement in August of its \$5.4 billion acquisition of Global Blood Therapeutics, another player in the sickle cell disease space. The Company owned shares in both Forma Therapeutics and Global Blood Therapeutics prior to their respective M&A announcements. We continue to believe M&A activity should increase given the low valuations of potential biotech targets, which should help catalyze a sustained recovery for biotech.

Biogen, Forma Therapeutics, and Iveric Bio were the largest positive contributors to performance during the month. In late September, Biogen's shares appreciated substantially after announcing the pivotal Phase 3 trial of lecanemab for Alzheimer's disease met its primary endpoint with a clinically meaningful effect size that was above consensus expectations. This is a notable positive development for the industry, as Alzheimer's represents a significant unmet medical need with large market potential. Forma Therapeutics' stock rallied after Novo Nordisk announced it had entered into an agreement to acquire Forma for \$1.1 bn. Shares of Iveric Bio increased after the company announced positive results from its Phase 3 study evaluating its drug Zimura to treat geographic atrophy.

GH Research, ALX Oncology, and Jounce Therapeutics were the largest negative contributors to performance during the month. GH Research and ALX Oncology underperformed in September on no fundamental news, after rallying strongly the previous month. Jounce Therapeutics' share price declined after disclosing its Phase 2 SELECT study did not meet its primary endpoint in lung cancer.

Discount / Premium Control Mechanism

The Directors have adopted an active discount management policy to establish and support an improved rating in the Company's shares through the use of share buybacks, with a view to limiting the discount to NAV per share at which the shares trade to no more than 6%. Shares bought back will be cancelled.

How to Contact Us

Frostrow Capital LLP
25 Southampton Buildings
London, WC2A 1AL

Tel.: 0203 008 4910
Fax: 0203 043 8889

Website: www.frostrow.com
Email: info@frostrow.com



Risk Warnings

This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Company and has not been prepared in connection with any such offer or invitation. Before investing in the Company, or any other investment product, you should satisfy yourself as to its suitability and the risks involved, and you may wish to consult a financial adviser.

Any return you receive depends on future market performance and is uncertain. The Company does not seek any protection from future market performance so you could lose some or all of your investment. Shares of the Company are bought and sold on the London Stock Exchange (LSE). The price you pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company. Usually, at any given time, the price you pay for a share will be higher than the price you could sell it. For further information on the principal risks the Company is exposed to please refer to the Company's Annual Report or Investor Disclosure Document available at www.biotechgt.com. The Company can borrow to purchase investments, this could potentially magnify any losses or gains made by the Company.

Important Information

The Biotech Growth Trust PLC is a public limited company whose shares are premium listed on the LSE and is registered with HMRC as an investment trust. The Company has an indeterminate life, although shareholders consider and vote on the continuation of the Company every five years (the next such vote will be held in 2025).